Plato Investment Management Ltd Buys 1,391 Shares of Boston Scientific Co. (NYSE:BSX)

Plato Investment Management Ltd lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 8.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,751 shares of the medical equipment provider’s stock after acquiring an additional 1,391 shares during the quarter. Plato Investment Management Ltd’s holdings in Boston Scientific were worth $1,444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in BSX. Sierra Summit Advisors LLC bought a new position in Boston Scientific during the 4th quarter worth approximately $8,038,000. TD Asset Management Inc raised its stake in Boston Scientific by 10.7% during the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after buying an additional 155,565 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Boston Scientific by 225.6% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock valued at $7,237,000 after buying an additional 73,219 shares during the period. BDF Gestion bought a new stake in Boston Scientific during the second quarter valued at $3,570,000. Finally, Precision Wealth Strategies LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $956,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now directly owns 40,188 shares in the company, valued at $2,978,734.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 20,949 shares of company stock worth $1,627,877 in the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.6 %

NYSE BSX opened at $83.31 on Monday. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $122.68 billion, a P/E ratio of 70.01, a PEG ratio of 2.75 and a beta of 0.79. The business has a fifty day simple moving average of $78.08 and a 200 day simple moving average of $74.16. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $84.11.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the prior year, the company posted $0.53 earnings per share. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, analysts predict that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft boosted their price objective on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday, July 25th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Boston Scientific in a report on Thursday, July 25th. Evercore ISI lifted their price objective on shares of Boston Scientific from $78.00 to $81.00 and gave the company an “outperform” rating in a research note on Tuesday, July 2nd. Robert W. Baird increased their target price on shares of Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, Canaccord Genuity Group raised their price target on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.38.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.